Global Leukemia Therapeutics Market 2016-2020

Global Leukemia Therapeutics Market 2016-2020

  • September 2016 •
  • 110 pages •
  • Report ID: 4188389 •
  • Format: PDF
About Leukemia

Cancer that starts from hematopoietic stem cells of the bone marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. Also, based on the bone marrow cells from which cancer starts, leukemia can be categorized as lymphocytic or myeloid.

Technavio’s analysts forecast the leukemia therapeutics market to grow at a CAGR of 8.44% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the leukemia therapeutics market for 2016-2020. To calculate the market size, the report considers the the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of different types of leukemias.

The market is divided into the following segments based on geography:
- Americas

Technavio's report, Leukemia Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
- F. Hoffmann-La Roche
- Novartis
- Bristol-Myers Squibb
- AbbVie
- Teva Pharmaceuticals

Other prominent vendors
- Altor BioScience
- Amgen
- ARIAD Pharmaceuticals
- Arno Therapeutics
- Astex Pharmaceuticals
- AstraZeneca
- Baxter Healthcare
- Bayer HealthCare
- Bellicum Pharmaceuticals
- Biogen
- Boehringer Ingelheim
- BioLineRx
- Boston Biomedical
- Celator Pharmaceuticals
- Celgene
- CTI BioPharma
- Chroma Therapeutics
- Chugai Pharmaceutical
- Cyclacel Pharmaceuticals
- Daiichi Sankyo
- Eisai
- Emergent BioSolutions
- Erytech Pharma
- Fate Therapeutics
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- iDD biotech
- Immune Pharmaceuticals
- Immunomedics
- Infinity Pharmaceuticals
- Innate Pharma
- Jazz Pharmaceuticals
- Juno Therapeutics
- Karyopharm Therapeutics
- Ligand Pharmaceuticals
- MEDA Pharmaceuticals
- MedImmune
- Merck
- Midas Pharma
- Molecular Templates
- MorphoSys
- Nippon Shinyaku
- Novo Nordisk
- Onconova Therapeutics
- Ono Pharmaceuticals
- Orphan Europe
- Otsuka
- Pfizer
- Portola Pharmaceuticals
- Regeneron Pharmaceuticals
- Sanofi
- Sigma-Tau Pharmaceuticals
- Stemline Therapeutics
- Sunesis Pharmaceuticals
- TG Therapeutics
- TheraMAB
- Tolero Pharmaceuticals
- XEME Biopharma
- Xencor
- ZIOPHARM Oncology

Market driver
- Technological advances in the monitoring of leukemia
- For a full, detailed list, view our report

Market challenge
- Limitations associated with current therapeutic options
- For a full, detailed list, view our report

Market trend
- Rise in the development of combination therapies
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.